73 -1 (33) 2021 — Musaeva R.Kh. ASSESSMENT AND PREDICTION OF THE CLINICAL COURSE OF CHF IN PATIENTS WITH MYOCARDIAL REVASCULARIZATION

ASSESSMENT AND PREDICTION OF THE CLINICAL COURSE OF CHF IN PATIENTS WITH MYOCARDIAL REVASCULARIZATION

Musaeva R.Kh.-Bukhara State Medical Institute

Resume

 Chronic heart failure (CHF) is one of the most common, progressive and prognostically unfavorable diseases of the cardiovascular system, the social significance of which is determined by the high mortality rate of patients, the most common cause of hospitalization, deterioration in the quality of life (QOL) and disability of patients [1,2]. The results of the study showed that the clinical course of the disease and LV systolic dysfunction are associated with the degree of occlusion of the coronary arteries. Severe lesions of the coronary arteries – 85-95% and total occlusion were significantly more frequent in the group of patients with reduced LV systolic function (EF <40%) and a relationship was revealed between the progression of the disease, as well as an increase in volume parameters – end-diastolic and end-systolic volumes LV with degree of occlusion

Key words: Assessment and prognosis of the clinical course of chronic heart failure, patients with myocardial revascularization.

First page

385

Last page

389

For citation: Musaeva R.Kh. Assessment and prediction of the clinical course of chf in patients with myocardial revascularization//New Day in Medicine 1(33) 2021 385-389. https://cutt.ly/nvR3t6H

LIST OF REFERENCES

1. Douglas L., Mann G., Felke M. Heart Failure: A Companion to Braunwald’s
2. Heart Disease. 10th addition, 2015: 762р.
3. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2016. European Heart Journal, 2016; 37 (27): 2129-2200.
4. Habal M.V., Liu P.P., Austin P.C. et al. Association of heart rate at hospital discharge with mortality and hospitalizations in patients with heart failure. Circ Heart Fail, 2014; 7: 12-20.
5. Osipova OA, Petrova GD, Shekhovtsova LV, Nagibina AI and others. The main pathogenetic mechanisms of the development of chronic heart failure against the background of ischemic heart disease. Scientific Bulletin of Belgorod State University, 2015: 4 (201): 29: 11-15.
6. Yancy C.W., Jessup M. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation, 2016; 134: e282.
7. Windecker S., Kolh P., F.Alonso 2014 ESC/EACTS Guildelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology(ESC) and the European Association for Cardio-Thoratic Surgery(EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular  Intervention (EAPCI). 2014.-Vol.35,№37.P.2541-2619.
8. Gautier S.V., Mironkov A.B., Sakhovsky S.A. Evaluation of the efficiency of myocardial revascularization in potential heart recipients with chronic ischemic heart failure. Bulletin of Transplantology and Artificial Organs. 2018; 20 (1): 39–44.
9. Rayol S.C., Sá M.P.B.O., Cavalcanti L.R.P.et al. Current Practice of State- of-the-Art Coronary Revascularization in Patients with Heart Failure. Braz J Cardiovasc Surg. 2019 Jan-Feb; 34(1): 93–97.
10. Khazova E.V., Bulashova O.V., Malkova M.I. A new approach to predicting the outcomes of chronic heart failure. Practical Medicine 2014; 6: 101-104.
11. Hwang S.J., Melenovsky V., Borlaug B.A. Implications of coronary artery disease in heart failure with preserved ejection fraction. J Am Coll Cardiol, 2014; 63: 2817–2827.